Hyperium

Rilmenidine, the active ingredient in Hyperium, is an imidazoline receptor agonist presented as an oral tablet for oral administration. It selectively reduces sympathetic nervous system activity, leading to a decrease in peripheral vascular resistance and lowering of blood pressure in adults diagnosed with essential hypertension, and improving overall cardiovascular risk profile as part of standard antihypertensive therapy.

GNH USA supplies Hyperium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple regions.

Rilmenidine is indicated for the treatment of essential hypertension, a chronic condition in which arterial pressure remains persistently elevated, increasing cardiovascular risk. The drug is used in adult patients to achieve and maintain blood pressure within guideline‑recommended targets, either as initial therapy or as part of a combination regimen when additional control is required.

Essential hypertension: lowers systolic and diastolic blood pressure, helping patients reach target blood pressure levels.

Rilmenidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivary secretion leading to throat discomfort. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Fatigue: generalized tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Nausea: feeling of stomach upset, sometimes with vomiting. - Constipation: decreased bowel movements and hard stools.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Syncope: sudden loss of consciousness related to low blood pressure. - Hepatic dysfunction: abnormal liver enzymes indicating possible liver injury. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Neutropenia: reduced white blood cell count increasing infection risk. - Cardiac arrhythmia: irregular heart rhythm that may require medical attention.

Before initiating therapy with Hyperium, several precautions should be considered to ensure safe use.

Monitor blood pressure: regularly check to avoid excessive hypotension. Assess renal function: evaluate kidney status and adjust dose if impairment is present. Avoid abrupt discontinuation: tapering may be needed to prevent rebound hypertension. Caution in elderly patients: increased sensitivity to hypotensive effects warrants careful dosing. Pregnancy and lactation: use only if potential benefits outweigh risks, as safety data are limited. Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Rilmenidine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant central antihypertensives (e.g., clonidine, methyldopa): additive hypotensive effect may cause severe blood pressure drop. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase rilmenidine plasma concentrations. - MAO inhibitors: risk of unpredictable blood pressure changes.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and renal function for additive effects. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response. - Alcohol: can enhance dizziness and hypotension. - Other imidazoline agonists: combined use may increase adverse events.